Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.7 |
mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |
mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.7 |
mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | Epothilone B | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | Epothilone B | FIMM | pan-cancer | AAC | 0.072 | 0.7 |
mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.022 | 0.7 |
mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |